Log in to your Inderes Free account to see all free content on this page.
Genmab
1,545
DKK
+0.88 %
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
23 following
+0.88%
-0.23%
-17.38%
-20.91%
-28.31%
-28.41%
-37.12%
-3.07%
+4,430.79%
www.genmab.com/investors
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Revenue
16.47B
EBIT %
32.3 %
P/E
23.18
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GMAB
Daily low / high price
1,535 / 1,555.5
DKK
Market cap
102.24B DKK
Turnover
12.73M DKK
Volume
8.2K
ShowingAll content types
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Genmab to Present at Citi’s Global Healthcare Conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio